Ixekizumab Associated New-Onset Inflammatory Bowel Disease

Amir Nazarian; Andrea Grin; Don Thiwanka Wijeratne

doi:10.14309/crj.0000000000000316

Ixekizumab Associated New-Onset Inflammatory Bowel Disease

ACG Case Rep J. 2020 Mar 2;7(2):e00316. doi: 10.14309/crj.0000000000000316. eCollection 2020 Feb.

Authors

Amir Nazarian¹, Andrea Grin², Don Thiwanka Wijeratne¹

Affiliations

¹ Department of Medicine, Queen's University, Kingston, Ontario, Canada.
² Department of Pathology, Queen's University, Kingston, Ontario, Canada.

Abstract

Ixekizumab is a monoclonal antibody targeting interleukin-17 approved for the treatment of psoriasis. In a recent post hoc meta-analysis of Phase-I to Phase-III clinical trials of anti-interleukin-17 agents for the treatment of plaque psoriasis, there was a rare association (<1%) with induction or exacerbation of inflammatory bowel disease. We report a case of new-onset ileal Crohn's disease in a 48-year-old woman on ixekizumab for psoriasis.

Publication types

Case Reports